Production (Stage)
Alnylam Pharmaceuticals, Inc.
ALNY
$314.94
-$7.70-2.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -57.48M | -83.76M | -111.57M | -16.89M | -65.94M |
| Total Depreciation and Amortization | 14.41M | -20.55M | 27.04M | 24.69M | 13.52M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 141.81M | 83.86M | 97.51M | 165.66M | 79.36M |
| Change in Net Operating Assets | -217.05M | -74.21M | 30.73M | -49.30M | -108.46M |
| Cash from Operations | -118.31M | -94.66M | 43.71M | 124.16M | -81.52M |
| Capital Expenditure | -8.97M | -9.09M | -4.19M | -8.02M | -12.97M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 122.74M | -43.82M | -26.06M | 41.96M | -54.65M |
| Cash from Investing | 113.77M | -52.91M | -30.25M | 33.94M | -67.62M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 49.37M | 36.28M | 108.04M | 132.78M | 25.86M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.28M | -5.28M | -5.28M | -1.28M | 3.05M |
| Cash from Financing | 44.08M | 31.00M | 102.76M | 131.50M | 28.91M |
| Foreign Exchange rate Adjustments | 14.06M | -17.27M | 15.09M | -3.12M | -9.94M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.60M | -133.85M | 131.31M | 286.47M | -130.17M |